Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.
Rebecca Kristeleit, BSc, PhD
Advertisement
Articles by Rebecca Kristeleit, BSc, PhD
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the phase 3 ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, on efficacy outcomes from the 3-year follow-up for patients with advanced ovarian cancer in the ATHENA-MONO study.
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.
Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the safety profile of rucaparib in the treatment of patients with ovarian cancer.
Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the efficacy of rucaparib in the treatment of patients with ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Kristeleit on QoL With Dostarlimab in dMMR/MSI-H Endometrial CancerSeptember 30th 2020
Dr. Kristeleit on the Efficacy of Rucaparib in Ovarian CancerJanuary 9th 2017
Dr. Kristeleit on the Safety Profile of Rucaparib in Ovarian CancerJanuary 17th 2017
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
3
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5